Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6286 to 6300 of 8937 results

  1. What interventions are effective and cost effective in supporting return to work, in all workplaces including micro-, small- and medium-sized organisations, after long-term sickness absence in the UK?

    Recommendation ID NG146/1 Question What interventions are effective and cost effective in supporting return to work, in all workplaces

    Research recommendation
    Published
    10 February 2020

  2. Intermittent urinary catheters: catheter selection:- For patients performing intermittent self-catheterisation over the long term, what is the clinical and cost effectiveness of single-use non-coated versus single-use hydrophilic versus single-use gel reservoir versus reusable non-coated catheters with regard to the following outcomes: symptomatic urinary tract infections, urinary tract infection-associated bacteraemia, mortality, patient comfort and preference, quality of life, and clinical symptoms of urethral damage?

    Recommendation ID CG139/3 Question Intermittent urinary catheters: catheter selection:- For patients performing intermittent self-catheterisation

    Research recommendation
    Published
    9 June 2015

  3. The committee also noted that the additional evidence exploring the relationship between radiological measures of bone defects (that is, the Rickets Severity Score and the Radiographic Global Impression of Change) and health-related quality of life would help to address several key uncertainties in the economic analysis.

    Recommendation ID HST8/2 Question The committee also noted that the additional evidence exploring the relationship between radiological

    Research recommendation
    Published
    22 March 2019

  4. Additional maintenance therapy for asthma uncontrolled on a moderate dose of ICS plus LABA with or without LTRA:- What is the clinical and cost effectiveness of offering additional maintenance therapy to adults, young people and children with asthma that is uncontrolled on a moderate dose of ICS plus LABA with or without LTRA?

    Recommendation ID NG80/8 Question Additional maintenance therapy for asthma uncontrolled on a moderate dose of ICS plus LABA with or without

    Research recommendation
    Published
    18 October 2018

  5. Additional assessments:- Do additional assessments (for IQ, language ability and motor ability) improve accuracy in diagnosing autism among preschool children (younger than 5 years) compared with signs and symptoms alone?

    Recommendation ID CG128/3 Question Additional assessments:- Do additional assessments (for IQ, language ability and motor ability) improve

    Research recommendation
    Published
    9 June 2015

  6. Advance statements and decisions:- What forms of management of violence and aggression do service users prefer and do advance statements and decisions have an important role in management and prevention?

    Recommendation ID NG10/3 Question Advance statements and decisions:- What forms of management of violence and aggression do service users

    Research recommendation
    Published
    1 October 2015

  7. What are the most effective and cost-effective frequencies for monitoring people with unruptured abdominal aortic aneurysms (AAA) of different diameters, and what is the optimal AAA threshold size (inner-to-inner maximum anterior-posterior diameter on ultrasound) for repair?

    Recommendation ID NG156/1 Question What are the most effective and cost-effective frequencies for monitoring people with unruptured abdominal

    Research recommendation
    Published
    10 August 2020

  8. What are the benefits, risk and cost effectiveness of enteral nutrition in maintaining remission in the post-surgical period of Crohn's disease?

    Recommendation ID NG129/1 Question What are the benefits, risk and cost effectiveness of enteral nutrition in maintaining remission in

    Research recommendation
    Published
    25 October 2019

  9. 5-aminosalicylate (5-ASA) treatment:- Following successful medical induction of remission of Crohn's disease of the colon, is mesalazine more clinically and cost effective than no treatment?

    Recommendation ID CG152/3 Question 5-aminosalicylate (5-ASA) treatment:- Following successful medical induction of remission of Crohn's

    Research recommendation
    Published
    17 September 2020

  10. Novel endovascular interventions: What is the clinical and cost effectiveness of novel endovascular techniques and devices such as coated coils, endoluminal flow diverters and intrasaccular devices to treat aneurysmal subarachnoid haemorrhage?

    Recommendation ID NG228/04 Question Novel endovascular interventions: What is the clinical and cost effectiveness of novel endovascular

    Research recommendation
    Published
    12 December 2022

  11. Follow-up strategies: What is the clinical and cost effectiveness of patient-initiated follow-up compared with routine follow-up for people with osteoarthritis?

    Recommendation ID NG226/04 Question Follow-up strategies: What is the clinical and cost effectiveness of patient-initiated follow-up compared

    Research recommendation
    Published
    7 November 2022

  12. Oxygen therapy for OSAHS: What is the clinical and cost effectiveness of nocturnal oxygen compared with placebo in people with OSAHS who are unable to tolerate CPAP?

    Recommendation ID NG202/9 Question Oxygen therapy for OSAHS: What is the clinical and cost effectiveness of nocturnal oxygen compared with

    Research recommendation
    Published
    30 September 2021

  13. What is the clinical and cost effectiveness of omega-3 fatty acids in the treatment of children and young people considered to be at high risk of developing psychosis?

    Recommendation ID CG155/2 Question What is the clinical and cost effectiveness of omega-3 fatty acids in the treatment of children and

    Research recommendation
    Published
    9 June 2015

  14. Risk of systemic anticancer treatment in people with cancer and COVID-19: Are patients with cancer and COVID-19 who are receiving/have recently received systemic anticancer treatment (SACT) (that is, within the 4 weeks preceding a diagnosis of COVID-19) at increased risk of severe COVID-19 illness or death?

    Recommendation ID NG161/1 Question Risk of systemic anticancer treatment in people with cancer and COVID-19: Are patients with cancer and

    Research recommendation
    Published
    21 October 2021

  15. Risk of radiotherapy in people with cancer and COVID-19: Are patients with cancer and COVID-19 who are receiving/have recently received radiotherapy (that is, within the 4 weeks preceding a diagnosis of COVID-19) at increased risk of severe COVID-19 illness or death?

    Recommendation ID NG162/1 Question Risk of radiotherapy in people with cancer and COVID-19: Are patients with cancer and COVID-19 who are

    Research recommendation
    Published
    21 October 2021